Nkarta, Inc. Stock Price, News & Analysis

Nkarta (NASDAQ:NKTX) reported third-quarter 2025 results and clinical progress for its NKX019 autoimmune program on Nov 10, 2025. Key points: $316.5 million cash and investments at Sept 30, 2025, expected to fund operations into 2029; enrollment began in the second dose-escalation cohort after a combined iDSMB cleared simultaneous dosing across Ntrust-1 and Ntrust-2; modified lymphodepletion with fludarabine plus cyclophosphamide produced complete B-cell depletion in treated patients versus partial depletion with cyclophosphamide alone. Initial NKX019 data are planned for a medical conference in 2026.

Nkarta (Nasdaq: NKTX) will participate in two investor conferences in November 2025: a Stifel 2025 Healthcare Conference fireside chat on November 12, 2025 at 10:40 a.m. ET and a TD Cowen Immunology & Inflammation Summit fireside chat on November 13, 2025 at 5:00 p.m. ET. A simultaneous webcast will be available on the company’s Investors website at www.nkartatx.com, and a replay will be archived on the site for approximately 90 days.

Nkarta (Nasdaq: NKTX) will present a poster at ACR Convergence 2025 in Chicago on Sunday, October 26, 2025, reporting clinical and preclinical data for its investigational therapy NKX019.

Data to be presented show robust CD19+ B‑cell depletion with subsequent B‑cell reconstitution consistent with immune reset in participants with non‑Hodgkin lymphoma, plus preclinical results showing depletion of pathogenic B cells in in vivo lymphoma models and in vitro autoimmune models and trafficking to lymphoid organs.

Poster details: Presenting author Mira Tohmé; time 10:30 AM–12:30 PM CT; room Hall F1; poster number 0014. Nkarta will also exhibit at booth #1801.

Nkarta (NASDAQ:NKTX), a clinical-stage biopharmaceutical company focused on engineered natural killer (NK) cell therapies, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company will engage in a fireside chat on September 9, 2025, at 8:30 a.m. ET.

Investors can access a live webcast of the presentation through Nkarta's website, with a replay available for approximately 90 days following the event.

Nkarta (NASDAQ: NKTX), a clinical-stage biopharmaceutical company developing NK cell therapies, reported its Q2 2025 financial results. The company maintains a strong financial position with $334.0 million in cash and investments as of June 30, 2025, expected to fund operations into 2029.

Key financial metrics include R&D expenses of $20.8 million, G&A expenses of $6.4 million, and a net loss of $23.0 million ($0.31 per share). The company appointed Dr. Shawn Rose as Chief Medical Officer and Head of R&D in June 2025, strengthening its clinical leadership in autoimmune diseases.

Nkarta plans to release preliminary data from Ntrust-1 and Ntrust-2 clinical trials for NKX019 in multiple autoimmune indications in H2 2025.

Nkarta (NASDAQ:NKTX), a clinical-stage biopharmaceutical company focused on engineered natural killer (NK) cell therapies, has announced its participation in the upcoming H.C. Wainwright "HCW@Home" Series. The company will engage in a fireside chat on July 30, 2025, at 11:00 a.m. ET.

Investors can access the webcast through registration or via the Investors section of Nkarta's website. A replay will be available on www.nkartatx.com for approximately 90 days following the event.

Nkarta (NKTX) announced the appointment of Shawn Rose, M.D. Ph.D., as Chief Medical Officer and Head of R&D, effective June 23, 2025. Dr. Rose, who brings extensive experience in immunology and drug development, replaces David R. Shook, M.D. Dr. Rose previously served as Chief Development Officer at Vividion Therapeutics and has contributed to developing approved medicines like Sotyktu, Stelara, and Tremfya. His appointment aligns with Nkarta's strategic focus on using their NK cell platform to treat autoimmune diseases. Dr. Rose's background includes leadership roles at Magenta Therapeutics, Annexon Biosciences, Janssen Pharmaceuticals, and Bristol-Myers Squibb. Dr. Shook will remain as a consultant through July 11 before pursuing opportunities in oncology.

Nkarta (NKTX) reported its Q1 2025 financial results and corporate updates. The company holds a strong cash position of $351.9 million, expected to fund operations into 2029. Key highlights include ongoing enrollment in multiple clinical trials for NKX019, including the Ntrust-1 trial (expanded to include primary membranous nephropathy), Ntrust-2 trial, and investigator-sponsored trials for myasthenia gravis and systemic lupus erythematosus. The company modified its lymphodepletion regimen across platforms to include both fludarabine and cyclophosphamide. Initial clinical data from Ntrust trials is expected in H2 2025. Financially, Nkarta reported a Q1 net loss of $32.0 million ($0.43 per share) and implemented a restructuring plan reducing workforce by 34% to extend cash runway.

Nkarta (Nasdaq: NKTX), a biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference.

The company will engage in a fireside chat scheduled for April 8, 2025, at 11:00 a.m. ET. Investors and interested parties can access a live webcast of the event through the Investors section of Nkarta's website. The presentation recording will remain available on www.nkartatx.com for approximately 90 days following the event.